Asthma is a chronic condition of the lungs that involves inflammation and hyperactivity of the airways. Severe asthma is a type of asthma that does not respond well to standard asthma treatments. The symptoms by definition, are more intense than regular asthmatic symptoms and can last for prolonged periods.
Eosinophilic Asthma is a type of Severe Asthma. It is described by high levels of white blood cells. These white blood cells called Eosinophils, are part of the body’s immune system. Their work is to fight infections and prevent the body from harmful bacteria attacks. In people with Eosinophilic Asthma theses, white blood cells cause inflammation in the respiratory system. The symptoms of asthma can be more severe due to the higher levels of Eosinophils in the body.
DelveInsight’s “Eosinophilic Asthma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Eosinophilic Asthma, historical and forecasted epidemiology as well as the Eosinophilic Asthma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Eosinophilic Asthma Market Report:
- The exact prevalence of Eosinophilic Asthma is still unknown
- The prevalence of Eosinophilic Asthma is more in females than in males
- According to the researchers, about 5% of all the adults suffer from Eosinophilic Asthma
- Around 25 million people in the United States are suffering from Asthma
- Among all the asthmatic patients, around 32-40% patients have a prevalence of Eosinophilic Asthma
Request a sample for the Report: https://www.delveinsight.com/sample-request/eosinophilic-asthma-market
The symptoms of can be unpredictable and occur during the day and night. The common symptoms of Eosinophilic Asthma include-
- Coughing
- Shortness in breathing
- Tightness in the chest
- Pain in Chest
- Asthma Attacks
- Wheezing
- Difficulty in breathing
Eosinophilic Asthma Market
The dynamics of the Eosinophilic Asthma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as ANB020, Reslizumab, OC000455, and others during the forecasted period 2019-2032.
Learn more by requesting for sample @Eosinophilic Asthma Market Landscape
Eosinophilic Asthma Pipeline Therapies:
- ANB020
- Reslizumab
- Dexpramipexole
- Symbicort®
- OC000459
Eosinophilic Asthma Pipeline Key Companies:
- Chiesi Farmaceutici
- Atopix Therapeutics
- Teva Branded Pharmaceutical
- Chemlmmune Therapeutics
- Knopp Biosciences
- Sanofi
Click here to read more about Eosinophilic Asthma Market Outlook 2032
Related Reports:
Asthma Pipeline
"Asthma Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Eosinophilic Asthma market. A detailed picture of the Eosinophilic Asthma pipeline landscape is provided, which includes the disease overview and Eosinophilic Asthma treatment guidelines.
Asthma Epidemiology
DelveInsight's 'Asthma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Eosinophilic Asthma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
